Merck & Co. Company Profile (NYSE:MRK)

About Merck & Co.

Merck & Co. logoMerck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The Company's animal health products are sold to veterinarians, distributors and animal producers.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: Pharmaceuticals
  • Exchange: NYSE
  • Symbol: MRK
  • CUSIP: 58933Y10
Key Metrics:
  • Previous Close: $60.75
  • 50 Day Moving Average: $62.40
  • 200 Day Moving Average: $58.99
  • 52-Week Range: €47.97 - €64.86
  • Trailing P/E Ratio: 33.32
  • Foreward P/E Ratio: 15.74
  • P/E Growth: 2.69
  • Market Cap: $167.99B
  • Outstanding Shares: 2,765,208,000
  • Beta: 0.68
  • Net Margins: 13.01%
  • Return on Equity: 23.41%
  • Return on Assets: 10.45%
  • Debt-to-Equity Ratio: 0.54%
  • Current Ratio: 1.87%
  • Quick Ratio: 1.52%
Additional Links:
Companies Related to Merck & Co.:

Analyst Ratings

Consensus Ratings for Merck & Co. (NYSE:MRK) (?)
Ratings Breakdown: 11 Hold Ratings, 8 Buy Ratings
Consensus Rating:Hold (Score: 2.42)
Consensus Price Target: €65.33 (7.54% upside)

Analysts' Ratings History for Merck & Co. (NYSE:MRK)
DateFirmActionRatingPrice TargetDetails
10/16/2016Jefferies GroupReiterated RatingHold$65.00View Rating Details
10/13/2016Bank of America Corp.UpgradeNeutral -> Buy$57.00 -> $70.00View Rating Details
10/12/2016Leerink SwannReiterated RatingMarket Perform$65.00View Rating Details
10/12/2016Barclays PLCReiterated RatingOverweightView Rating Details
9/14/2016ArgusReiterated RatingBuy$65.00View Rating Details
9/13/2016Morgan StanleySet Price TargetHold$60.00View Rating Details
9/11/2016Berenberg BankReiterated RatingHold$62.00View Rating Details
8/11/2016Sanford C. BernsteinReiterated RatingOutperform$66.00 -> $74.00View Rating Details
8/10/2016Citigroup Inc.Reiterated RatingNeutral$65.00View Rating Details
8/8/2016Piper Jaffray Cos.Reiterated RatingNeutral$58.00 -> $62.00View Rating Details
8/8/2016Deutsche Bank AGBoost Price TargetHold$58.00 -> $59.00View Rating Details
8/7/2016Credit Suisse Group AGUpgradeNeutral -> Outperform$62.00 -> $73.00View Rating Details
8/5/2016BMO Capital MarketsUpgradeMarket Perform -> Outperform$62.00 -> $72.00View Rating Details
6/8/2016Goldman Sachs Group Inc.Reiterated RatingNeutral$60.00View Rating Details
5/19/2016JPMorgan Chase & Co.Reiterated RatingOverweightView Rating Details
4/6/2016Societe GeneraleInitiated CoverageBuyView Rating Details
2/5/2016S&P Equity ResearchReiterated RatingHold$56.00View Rating Details
2/3/2016Cowen and CompanyReiterated RatingHoldView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutralView Rating Details
(Data available from 10/24/2014 forward)


Earnings History for Merck & Co. (NYSE:MRK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/25/2016Q316$0.98$10.17 billionN/AView Earnings Details
7/29/2016Q216$0.91$0.93$9.79 billion$9.84 billionViewListenView Earnings Details
5/5/2016Q116$0.85$0.89$9.45 billion$9.30 billionViewN/AView Earnings Details
2/3/2016Q415$0.91$0.93$10.32 billion$10.22 billionViewListenView Earnings Details
10/27/2015Q315$0.91$0.96$10.11 billion$10.10 billionViewListenView Earnings Details
7/28/2015Q215$0.80$0.86$9.81 billion$9.80 billionViewListenView Earnings Details
4/28/2015Q115$0.75$0.85$9.04 billion$9.40 billionViewListenView Earnings Details
2/4/2015Q414$0.86$0.87$10.61 billion$10.48 billionViewListenView Earnings Details
10/27/2014Q314$0.88$0.90$10.66 billion$10.56 billionViewListenView Earnings Details
7/29/2014Q214$0.80$0.85$10.60 billion$10.93 billionViewListenView Earnings Details
4/29/2014Q114$0.79$0.88$10.44 billion$10.30 billionViewListenView Earnings Details
2/5/2014Q413$0.88$0.88$11.39 billion$11.30 billionViewListenView Earnings Details
10/28/2013Q313$0.88$0.92$11.19 billion$11.03 billionViewListenView Earnings Details
7/30/2013Q2 2013$0.82$0.84$11.22 billion$11.01 billionViewListenView Earnings Details
5/1/2013Q1 2013$0.79$0.85$11.09 million$10.70 millionViewListenView Earnings Details
2/1/2013Q4 2012$0.81$0.83$11.46 billion$11.70 billionViewListenView Earnings Details
10/26/2012Q312$0.92$0.95$11.60 billion$11.50 billionViewN/AView Earnings Details
7/27/2012$1.02$1.05ViewN/AView Earnings Details
4/27/2012$0.98$0.99ViewN/AView Earnings Details
2/2/2012$0.95$0.97ViewN/AView Earnings Details
10/28/2011$0.91$0.94ViewN/AView Earnings Details
7/29/2011$0.94$0.95ViewN/AView Earnings Details
4/29/2011$0.84$0.92ViewN/AView Earnings Details
2/3/2011$0.83$0.88ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Merck & Co. (NYSE:MRK)
Current Year EPS Consensus Estimate: $3.75 EPS
Next Year EPS Consensus Estimate: $3.86 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$0.82$0.87$0.84
Q2 20163$0.92$0.92$0.92
Q3 20163$0.97$0.99$0.98
Q4 20162$0.93$0.96$0.95
(Data provided by Zacks Investment Research)


Current Dividend Information for Merck & Co. (NYSE:MRK)
Annual Dividend:$1.84
Dividend Yield:3.03%
Dividend Growth:2.30% (3 Year Average)
Payout Ratio:101.10% (Based on Trailing 12 Months of Earnings)
49.07% (Based on Current Year Consensus EPS Estimate)
47.67% (Based on Next Year Consensus EPS Estimate)
Track Record:4 Years of Consecutive Dividend Growth

Dividend History for Merck & Co. (NYSE:MRK)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Merck & Co. (NYSE:MRK)
Insider Ownership Percentage: 0.05%
Institutional Ownership Percentage: 72.93%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/3/2016Weir Mirian M GraddickInsiderSell40,800€62.07€2,532,456.00View SEC Filing  
9/1/2016Adam H SchechterEVPSell39,200€62.61€2,454,312.00View SEC Filing  
8/10/2016Clark GolestaniEVPSell3,000€63.03€189,090.00View SEC Filing  
8/5/2016Kenneth C FrazierChairmanSell392,000€61.81€24,229,520.00View SEC Filing  
7/5/2016Kenneth C FrazierCEOSell60,000€58.00€3,480,000.00View SEC Filing  
7/5/2016Weir Mirian M GraddickInsiderSell45,000€57.99€2,609,550.00View SEC Filing  
7/1/2016Adam H SchechterEVPSell50,000€57.69€2,884,500.00View SEC Filing  
7/1/2016Weir Mirian M GraddickInsiderSell30,000€57.49€1,724,700.00View SEC Filing  
5/20/2016Clark GolestaniEVPSell39,877€54.79€2,184,860.83View SEC Filing  
4/14/2016Kenneth C FrazierCEOSell131,040€56.11€7,352,654.40View SEC Filing  
11/4/2015Wendell P. WeeksDirectorSell5,000€55.53€277,650.00View SEC Filing  
10/29/2015Adele D. AmbroseinsiderSell37,313€55.08€2,055,200.04View SEC Filing  
10/29/2015Kenneth C. FrazierCEOSell18,666€54.69€1,020,843.54View SEC Filing  
10/28/2015Peter C. WendellDirectorSell5,000€54.85€274,250.00View SEC Filing  
5/11/2015Adam H SchechterEVPSell10,634€60.44€642,718.96View SEC Filing  
5/8/2015Julie L GerberdingEVPSell38,368€60.99€2,340,064.32View SEC Filing  
5/4/2015Bruce N KuhlikInsiderSell56,064€60.20€3,375,052.80View SEC Filing  
4/29/2015Bruce N KuhlikInsiderSell156,902€59.82€9,385,877.64View SEC Filing  
4/29/2015Michael J HolstonEVPSell95,624€59.84€5,722,140.16View SEC Filing  
2/18/2015Kenneth C FrazierCEOSell5,164€58.67€302,971.88View SEC Filing  
2/11/2015Willie A DeeseInsiderSell135,864€58.56€7,956,195.84View SEC Filing  
2/9/2015Peter C WendellDirectorSell5,000€58.76€293,800.00View SEC Filing  
1/15/2015Adam H SchechterEVPSell74,200€62.48€4,636,016.00View SEC Filing  
1/9/2015Kenneth C FrazierCEOSell8,840€62.47€552,234.80View SEC Filing  
12/10/2014Kenneth C FrazierCEOSell9,846€60.00€590,760.00View SEC Filing  
12/8/2014Bruce N KuhlikInsiderSell50,000€62.00€3,100,000.00View SEC Filing  
11/26/2014Rochelle B LazarusDirectorSell10,000€59.63€596,300.00View SEC Filing  
11/24/2014Wendell P WeeksDirectorSell5,000€59.13€295,650.00View SEC Filing  
11/10/2014Kenneth C FrazierCEOSell10,000€57.98€579,800.00View SEC Filing  
10/10/2014Kenneth C FrazierCEOSell9,895€59.73€591,028.35View SEC Filing  
9/10/2014Kenneth C FrazierCEOSell9,814€60.48€593,550.72View SEC Filing  
8/25/2014Adam H SchechterEVPSell22,000€59.70€1,313,400.00View SEC Filing  
8/11/2014Kenneth C FrazierCEOSell10,058€57.00€573,306.00View SEC Filing  
8/4/2014Adele D AmbroseInsiderSell28,669€56.64€1,623,812.16View SEC Filing  
7/10/2014Kenneth C FrazierCEOSell9,987€58.03€579,545.61View SEC Filing  
7/7/2014Weir Mirian M GraddickInsiderSell180,047€59.16€10,651,580.52View SEC Filing  
6/27/2014Willie A DeeseInsiderSell72,290€58.26€4,211,615.40View SEC Filing  
6/10/2014Kenneth C FrazierCEOSell9,985€58.06€579,729.10View SEC Filing  
5/14/2014Adam SchechterEVPSell10,527€55.91€588,564.57View SEC Filing  
4/10/2014Kenneth FrazierCEOSell10,047€57.24€575,090.28View SEC Filing  
4/4/2014Bruce KuhlikInsiderSell145,225€56.43€8,195,046.75View SEC Filing  
2/14/2014Clark GolestaniEVPSell5,990€55.47€332,265.30View SEC Filing  
2/13/2014Bridgette HellerVPSell43,870€55.04€2,414,604.80View SEC Filing  
2/11/2014Adam SchechterEVPSell18,000€55.61€1,000,980.00View SEC Filing  
2/11/2014John CananInsiderSell10,000€55.70€557,000.00View SEC Filing  
2/11/2014Kenneth FrazierCEOSell41,520€54.52€2,263,670.40View SEC Filing  
2/10/2014Peter WendellDirectorSell5,000€54.44€272,200.00View SEC Filing  
2/10/2014Willie DeeseInsiderSell50,000€54.68€2,734,000.00View SEC Filing  
8/7/2013Willie DeeseInsiderSell50,638€48.55€2,458,474.90View SEC Filing  
5/15/2013Adele D AmbroseInsiderSell34,208€46.66€1,596,145.28View SEC Filing  
5/13/2013Bridgette P HellerVPSell5,404€46.15€249,394.60View SEC Filing  
8/9/2012Willie A DeeseInsiderSell62,324€44.26€2,758,460.24View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Merck & Co. (NYSE:MRK)
News Icon2 Stocks Analyst-Opinion Need Close Attention: Merck & Co., Inc. (NYSE:MRK), Sirius XM Holdings Inc. (NASDAQ:SIRI) - The Voice Registrar (NYSE:MRK) - October 24 at 5:58 PM logoWhat to Expect From Merck Earnings - 24/7 Wall St. (NYSE:MRK) - October 24 at 5:58 PM
News IconWorth Watching Stocks: Merck & Co., Inc. (NYSE:MRK), Abbott Laboratories (NYSE:ABT) - NYSE Journal (press release) (NYSE:MRK) - October 24 at 5:58 PM logoInteresting April 2017 Stock Options for MRK - Nasdaq (NYSE:MRK) - October 24 at 5:58 PM logoMerck Gets FDA Approval for Investigational Drug Zinplava (NYSE:MRK) - October 24 at 11:42 AM logoApple, GM, Lockheed Headline Key Earnings Tuesday: Investing Action Plan (NYSE:MRK) - October 24 at 11:42 AM logoBig News Out Of Merck This Weekend (NYSE:MRK) - October 24 at 10:47 AM
News IconAnalysts' Recommendations Stocks to Track: Merck & Co., Inc. (NYSE:MRK) & Reynolds American, Inc. (NYSE:RAI) - Money News (NYSE:MRK) - October 22 at 5:51 PM logoWill Merck (MRK) Stock Be Helped as Keytruda Meets Goal? - (NYSE:MRK) - October 22 at 10:20 AM logoFDA Approves Merck’s ZINPLAVA™ (bezlotoxumab) to Reduce Recurrence of Clostridium difficile Infection (CDI) in Adult Patients Receiving Antibacterial Drug Treatment for CDI Who Are at High Risk of CDI Recurrence (NYSE:MRK) - October 22 at 10:20 AM logoMerck & Co.'s 3Q16 Estimates: Expect Revenue Growth - Market Realist (NYSE:MRK) - October 21 at 6:17 PM logoMerck Set For Big Move After 3-Month Slumber (MRK) - Investopedia (NYSE:MRK) - October 21 at 6:17 PM logoWill Merck Report Another Healthy Quarter? (NYSE:MRK) - October 21 at 6:17 PM logoMerck Set For Big Move After 3-Month Slumber (MRK) (NYSE:MRK) - October 21 at 6:17 PM logoMerck Has An Upcoming PDUFA Date For Bezlotoxumab (NYSE:MRK) - October 21 at 5:24 PM
News IconAppraising The Value of These Shares: Merck & Co., Inc. (NYSE:MRK) - CSZ News (NYSE:MRK) - October 21 at 9:39 AM logoJim Cramer Gives His Opinion On Merck And Smith & Wesson - Benzinga (NYSE:MRK) - October 21 at 9:39 AM
News IconCalculating the intrinsic value of Merck & Co Inc (MRK) - Simply Wall St (NYSE:MRK) - October 21 at 9:39 AM logoNothing Can Stop Merck & Co., Inc. (MRK) Stock Now - (NYSE:MRK) - October 21 at 9:39 AM logoMerck’s KEYNOTE-045 Studying KEYTRUDA® (pembrolizumab) in Advanced Bladder Cancer (Urothelial Cancer) Meets Primary Endpoint and Stops Early (NYSE:MRK) - October 21 at 9:39 AM
News IconEastern Bank Lowers stake in Merck & Co. (MRK) (NYSE:MRK) - October 20 at 6:35 PM
News IconMerck & Co., Inc. (NYSE:MRK) earnings expectations | The ... - The Independent Republic (NYSE:MRK) - October 20 at 11:59 AM logoCan Merck (MRK) Keep the Earnings Streak Alive in Q3? - Nasdaq (NYSE:MRK) - October 20 at 11:59 AM
News IconHot Watch List- Merck & Co., Inc. (NYSE:MRK), Trex Co. Inc. (NYSE:TREX), Costamare Inc. (NYSE:CMRE) - Seneca Globe (NYSE:MRK) - October 20 at 11:59 AM logoMerck Now #22 Largest Company, Surpassing Intel (NYSE:MRK) - October 19 at 6:36 PM logoPreteens need only 2 HPV shots _ not 3, CDC says (NYSE:MRK) - October 19 at 6:36 PM
News IconMerck primes the market for its biosims with online effort targeting docs, patients (NYSE:MRK) - October 19 at 11:14 AM logoCan Merck (MRK) Keep the Earnings Streak Alive in Q3? (NYSE:MRK) - October 19 at 11:14 AM logoMerck Announces Pivotal Phase 3 Study of Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients, Met Primary Endpoint (NYSE:MRK) - October 19 at 11:14 AM logoWHO seeks new mechanism for crisis vaccine supplies at low cost (NYSE:MRK) - October 19 at 11:14 AM logoMerck Shares Up 19.0% Since SmarTrend's Buy Recommendation (MRK) (NYSE:MRK) - October 18 at 6:05 PM
News IconWatch List: Merck & Co., Inc. (NYSE:MRK) (NYSE:MRK) - October 18 at 6:05 PM logoRoche's lung cancer drug wins U.S. approval (NYSE:MRK) - October 18 at 6:05 PM logoStocks To Track: Kinder Morgan, Inc. (KMI), Merck & Co., Inc. (MRK), Micron Technology, Inc. (MU) (NYSE:MRK) - October 18 at 11:33 AM
News IconInvestment Looking For Stocks- Merck & Co., Inc. (NYSE:MRK), Bristol-Myers Squibb Firm (NYSE:BMY) - Seneca Globe (NYSE:MRK) - October 17 at 6:09 PM
News IconMerck & Co., Inc.'s (MRK): Major Stock of Recent Trade - Hot Stocks Point (NYSE:MRK) - October 17 at 6:09 PM logoMerck Research Laboratories Facilities Designated as “Milestones in Microbiology” Sites by the American Society for Microbiology (NYSE:MRK) - October 17 at 6:09 PM logoThe Zacks Analyst Blog Highlights: Mylan, Pfizer, Roche, Merck and Bristol-Myers (NYSE:MRK) - October 17 at 11:16 AM logoJohnson & Johnson’s Expected Profitability in 3Q16 (NYSE:MRK) - October 17 at 11:16 AM
News IconStocks in the Spotlight – Merck & Co., (NYSE:MRK), Provectus ... - Financial Breaking News (NYSE:MRK) - October 16 at 6:00 PM
News IconMerck & Co., Inc. (NYSE:MRK) – Top Stock from Healthcare Sector - The Daily Leicester (NYSE:MRK) - October 16 at 6:00 PM
News IconTrending Stocks - Merck, (NYSE:MRK), Williams Companies, (NYSE:WMB) (NYSE:MRK) - October 15 at 10:56 AM
News IconMerck KGaA (MRK) PT Set at €101.00 by Commerzbank AG (NYSE:MRK) - October 15 at 10:56 AM logoInvestor’s Alert: KeyCorp. (KEY), Merck & Co., Inc. (MRK), The Kroger Co. (KR) (NYSE:MRK) - October 14 at 6:01 PM
News IconMerck (MRK) Stock Higher on Ratings Upgrade (NYSE:MRK) - October 14 at 9:32 AM
News IconSteady Activities: Merck & Co., Inc. (NYSE:MRK) (NYSE:MRK) - October 14 at 9:32 AM logoTrade of the Day: Buy Merck & Co., Inc. (MRK) … But Not Yet (NYSE:MRK) - October 14 at 7:49 AM logoA Peek Into The Markets: U.S. Stock Futures Tumble Ahead Of Jobless Claims Report - Benzinga (NYSE:MRK) - October 13 at 9:48 AM logoMerck & Co., Inc. (MRK) Presents Strong Keytruda Data with High OS at ESMO, Shares Rise - TCC (NYSE:MRK) - October 13 at 9:48 AM logoAetna Inc (NYSE:AET), Merck & Co., Inc. (NYSE:MRK) Sign Value-Based Partnership - Market Exclusive (NYSE:MRK) - October 13 at 9:48 AM


Merck & Co. (NYSE:MRK) Chart for Monday, October, 24, 2016

Last Updated on 10/24/2016 by Staff